Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Burg, Bernhard Sixt, Nicolas Pasqual

Premium

Insight Genetics, based in Nashville, Tenn., said that David Burg has joined the company as associate director of business development. Burg will lead sales and marketing for the company's Insight Molecular Labs. Prior to joining Insight, Burg was regional sales director for Response Genetics. He has also been a senior executive oncology account manager with GlaxoSmithKline.


ImmunID announced that it has appointed Bernhard Sixt to be company president and CEO, and Nicolas Pasqual, the firm's co-founder and former CEO, to be its chief scientific officer. Sixt co-founded Agendia and served as its CEO from 2003 to 2011, and he has over 25 years of experience in the development and commercialization of diagnostics, pharmaceuticals, and lab services at companies like Amersham and Nycomed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.